Multi-Institutional Transgender & Gender-Diverse Breast Cancer Study
NCT ID: NCT06234488
Last Updated: 2026-01-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
125 participants
OBSERVATIONAL
2023-12-08
2026-08-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
BC Risk Assessment Before Top Surgery
NCT06239766
Transgender and Gender Diverse Individuals Screening for Breast Cancer
NCT06347393
Multiscale Omics for the Development of a Cohort Database and Study Platform in Breast Cancer Survivors
NCT04999826
Breast Cancer 2-PREVENT Translational Center of Excellence (TCE) - Metastatic Markers of Recurrent Tumor Phenotype for Breast Cancer
NCT02530008
MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ
NCT02352883
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Transgender and Gender-Diverse Persons with Breast Cancer
Patients who had a breast cancer diagnosis (including those with ductal carcinoma in situ (DCIS)), who were age ≥18 years at the time of diagnosis and identify as a gender and/or sex that is different from their sex assigned at birth (e.g., transgender, nonbinary, genderqueer, etc.) between 1/1/1990 - 7/1/2023.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Breast cancer diagnosis (including DCIS)
3. Persons who identify as gender and/or sex that is different from the sex they were assigned at birth
Exclusion Criteria
2. Cis-gendered persons
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medical College of Wisconsin
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Chandler S Cortina
Assistant Professor of Surgery
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Chandler S Cortina
Role: PRINCIPAL_INVESTIGATOR
The Medical College of Wisconsin
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Southern California/Los Angeles (USC/LA County)
Los Angeles, California, United States
University of California San Francisco (UCSF)
San Francisco, California, United States
University of Colorado Anschutz Medical Campus (CU Anschutz)
Aurora, Colorado, United States
MedStar Georgetown University Hospital (MGUH)
Washington D.C., District of Columbia, United States
Mayo Clinic
Jacksonville, Florida, United States
Moffitt Cancer Center (MCC)
Tampa, Florida, United States
Northwestern Medicine
Chicago, Illinois, United States
Rush University Medical Center
Chicago, Illinois, United States
NorthShore University Health System
Evanston, Illinois, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Birgham and Women's Hospital
Boston, Massachusetts, United States
Boston University (Boston U)
Boston, Massachusetts, United States
University of Michigan
Ann Arbor, Michigan, United States
Mayo Clinic
Rochester, Minnesota, United States
New York University (NYU)
New York, New York, United States
University of Rochester
Rochester, New York, United States
Duke University Medical Center
Durham, North Carolina, United States
Cleveland Clinic Foundation (CCF)
Cleveland, Ohio, United States
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
Vanderbilt University Medical Center (VUMC)
Nashville, Tennessee, United States
University of Washington (UW)
Seattle, Washington, United States
Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PRO00043417
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.